Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | APLNR | P35414 | 1/20 | 0.42 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA7 | P43166 | 2/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9176308 | 0.90 | CA2 (0.43) | CA12CA14CA2APLNRTDP1 | |
| SCHEMBL1060092 | 0.83 | CYP1A2 (0.46) | CA12CA14CA2APLNRGAA | |
| SCHEMBL3164804 | 0.82 | APLNR (0.43) | CA12CA14CA2APLNRTDP1 | |
| SCHEMBL19362876 | 0.81 | APLNR (0.46) | CA12CA14CA2APLNRTDP1 | |
| SCHEMBL523837 | 0.81 | CA2 (0.59) | CA12CA14CA2TET2RECQL | |
| SCHEMBL20759982 | 0.80 | MAOA (0.51) | CA12CA14CA2APLNRTDP1 | |
| SCHEMBL2671811 | 0.78 | APLNR (0.41) | CA12CA14CA2APLNRTDP1 | |
| SCHEMBL22946544 | 0.77 | APLNR (0.44) | CA12CA14CA2APLNRTDP1 | |
| SCHEMBL2776487 | 0.77 | APLNR (0.46) | CA12CA14CA2APLNRTDP1 | |
| SCHEMBL3177106 | 0.75 | APLNR (0.44) | CA12CA14CA2APLNRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111954673-B | New penam derivatives or salts thereof, pharmaceutical compositions and uses thereof | 富士胶片株式会社 | 2023-09-05 | — | — | CN | disclosed |
| WO-2022264114-A2 | ROS SENSITIVE DIAZABORINES FOR THE CONSTRUCTION OF STIMULI-RESPONSIVE BIOCONJUGATES | TECHNOPHAGE, INVESTIGAÇÃO E DESENVOLVIMENTO EM BIOTECHNOLOGIA, S.A. (PT) | 2022-12-22 | — | — | WO | disclosed |
| CN-114531850-A | Pharmaceutical composition and kit characterized by containing novel penicillin derivative or salt thereof and 1 or more compounds selected from beta-lactamase inhibitory compound and antibacterial compound or salt thereof | 富士胶片株式会社 | 2022-05-24 | — | — | CN | disclosed |
| WO-2021066149-A1 | PHARMACEUTICAL COMPOSITION AND KIT CHARACTERIZED BY CONTAINING NOVEL PENAM DERIVATIVE OR SALT THEREOF AND ONE OR MORE COMPOUNDS SELECTED FROM Β-LACTAMASE INHIBITOR COMPOUND, ANTIBACTERIAL COMPOUND AND SALTS OF THESE | 富士フイルム株式会社 | 2021-04-08 | — | — | WO | disclosed |
| CN-111954673-A | Novel penam derivative or salt thereof, pharmaceutical composition, and use thereof | 富士胶片株式会社 | 2020-11-17 | — | — | CN | disclosed |
| WO-2019194306-A1 | NOVEL PENAM DERIVATIVES OR SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | 富士フイルム株式会社 | 2019-10-10 | — | — | WO | disclosed |
| US-20030216441-A1 | Farnesyltransferase inhibitors | WEINSTOCK, STEVEN F. | 2003-11-20 | — | — | US | disclosed |
| US-5567840-A | AS 4-AMINOBUTYRIC ACID AGONIST; MUSCLE RELAXANTS | CIBA-GEIGY CORPORATION (US) | 1996-10-22 | — | — | US | disclosed |
| US-5461040-A | Therapy of spinal spacticity, multiple sclerosis, cerebral palsy, trigeminus neuralgia, drug withdrawal, pain | CIBA-GEIGY CORPORATION (US) | 1995-10-24 | — | — | US | disclosed |
| EP-0399949-B1 | Substituted aminoalkylphosphinic acids | CIBA GEIGY AG (CH) | 1995-04-12 | — | — | EP | disclosed |
| US-5281747-A | Pharmaceuticals | CIBA-GEIGY CORPORATION (US) | 1994-01-25 | — | — | US | disclosed |
| EP-0399949-A1 | Substituted aminoalkylphosphinic acids | CIBA-GEIGY AG (CH) | 1990-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216441-A1 | Farnesyltransferase inhibitors | FNTA, FNTB, LCAT | CA12 4109/4885CA14 3866/4885CA2 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.